Parra S - Search Results

1

Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients.

Parra S, Cabré A, Marimon F, Ferré R, Ribalta J, Gonzàlez M, Heras M, Castro A, Masana L. Parra S, et al. Lupus. 2014 Mar;23(3):245-54. doi: 10.1177/0961203313517405. Epub 2014 Jan 3. Lupus. 2014. PMID: 24390652

2

High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy.

Alonso-Villaverde C, Segues T, Coll-Crespo B, Pérez-Bernalte R, Rabassa A, Gomila M, Parra S, Gozález-Esteban MA, Jiménez-Expósito MJ, Masana L. Alonso-Villaverde C, et al. Among authors: parra s. AIDS. 2003 May 23;17(8):1173-8. doi: 10.1097/00002030-200305230-00009. AIDS. 2003. PMID: 12819519

3

Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele.

Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, Joven J, Masana L. Alonso-Villaverde C, et al. Among authors: parra s. Circulation. 2004 Oct 12;110(15):2204-9. doi: 10.1161/01.CIR.0000143835.95029.7D. Epub 2004 Oct 4. Circulation. 2004. PMID: 15466648

4

The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.

Alonso-Villaverde C, Coll B, Gómez F, Parra S, Camps J, Joven J, Masana L. Alonso-Villaverde C, et al. Among authors: parra s. AIDS. 2005 Feb 18;19(3):341-2. AIDS. 2005. PMID: 15718846

5

The stromal derived factor-1 mutated allele (SDF1-3'A) is associated with a lower incidence of atherosclerosis in HIV-infected patients.

Coll B, Alonso-Villaverde C, Parra S, Montero M, Tous M, Joven J, Masana L. Coll B, et al. Among authors: parra s. AIDS. 2005 Nov 4;19(16):1877-83. doi: 10.1097/01.aids.0000183516.22266.dd. AIDS. 2005. PMID: 16227796

6

HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1.

Coll B, Parra S, Alonso-Villaverde C, de Groot E, Aragonés G, Montero M, Tous M, Camps J, Joven J, Masana L. Coll B, et al. Among authors: parra s. Cytokine. 2006 Apr;34(1-2):51-5. doi: 10.1016/j.cyto.2006.03.013. Epub 2006 May 12. Cytokine. 2006. PMID: 16697654

7

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.

Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Masana L. Coll B, et al. Among authors: parra s. AIDS. 2006 Aug 1;20(12):1675-7. doi: 10.1097/01.aids.0000238418.43937.3b. AIDS. 2006. PMID: 16868453 Clinical Trial.

8

Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.

Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, Masana L, Ribalta J. Guardiola M, et al. Among authors: parra s. Clin Chem. 2006 Oct;52(10):1914-9. doi: 10.1373/clinchem.2006.069583. Epub 2006 Aug 3. Clin Chem. 2006. PMID: 16887900

9

Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy.

Coll B, Alonso-Villaverde C, Parra S, Rabassa A, Martorell L, Joven J, Masana L. Coll B, et al. Among authors: parra s. HIV Med. 2006 Sep;7(6):356-60. doi: 10.1111/j.1468-1293.2006.00392.x. HIV Med. 2006. PMID: 16903979 Free article.

10

Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection.

Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, Mackness M, Mackness B, Masana L, Joven J, Camps J. Parra S, et al. Atherosclerosis. 2007 Sep;194(1):175-81. doi: 10.1016/j.atherosclerosis.2006.07.024. Epub 2006 Aug 30. Atherosclerosis. 2007. PMID: 16942773

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters